Updated time: 2022-09-01 09:29:50
14A-1041022
TW I721136、US 11,207,289 B2、CN ZL 2017 8 0019116.1
A synthetic dihydrobenzofuran lignan (Q2-3), the dimerization product of plant caffeic acid methyl ester, was evaluated for suppressing 4T1 metastasis that involves fibroblastic IL-25 activity. Subsequent in vivo experiment showed that anti-metastatic effects of Q2-3 on 4T1 and human MDA-MD-231 tumor cells was additive when employed in combination with the clinically used drug, docetaxel.
The findings reveal the pharmacological mechanism of this synthetic compound (Q2-3), in particular by stimulating IL-25 produced in fibroblasts. In addition, this compound also confers additive anti-metastatic activity to clinical used drugs. It is the only natural product derivative that claims its regulatory activity in tumor microenvironment, and thus can inhibit the metastasis of both mouse and human mammary tumor cells in vivo.
Previously published literature related to this finding only indicated the cytotoxicity of Q2-3 in vitro, however failed to indicate its actual scope of application in cancer therapy.
- The effective application Q2-3 compound to fight/prevent metastasis of cancer clinical use.
- Development of natural products used in medical market of cancer treatment.
Ning-Sun Yang, Yueh-Hsiung Kuo, Shu-Yi Yin, Yung-Hsiang Chen
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Application of specific dihydrobenzofuran lignan for suppressing metastasis of mammary tumor cells